Business Context and Reporting Period
Unicycive Therapeutics, Inc. (UNCY), a Delaware corporation, filed this Form 8-K on July 9, 2024. The company is an emerging growth company with its principal executive offices in Los Altos, California. The filing addresses regulatory notices received from the Nasdaq Stock Market regarding compliance with continued listing standards.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on regulatory compliance status regarding stock price and market value.
Material Changes and Regulatory Notices
- Minimum Bid Price Deficiency: On July 9, 2024, the Company received notice that its common stock closed below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
- Market Value of Listed Securities (MVLS) Deficiency: On July 11, 2024, the Company received notice that its MVLS was below the required $35 million for 30 consecutive business days, violating Nasdaq Listing Rule 5550(b)(2).
- Compliance Deadlines: The Company has 180 calendar days to regain compliance for both issues. The deadline for the bid price requirement is January 6, 2025, and for the MVLS requirement is January 7, 2025.
- Current Status: The notices do not result in immediate delisting. The stock continues to trade on the Nasdaq Capital Market under the symbol "UNCY."
Outlook, Management Commentary, and Risks
Management intends to actively monitor the closing bid price and market value of its securities. The Company may consider implementing available options to regain compliance, though specific strategies are not detailed. There is no assurance that the Company will successfully maintain its listing. If compliance is not achieved by the respective deadlines, the Company may qualify for a second 180-day period or face delisting, at which point it would have the option to appeal to a Nasdaq hearings panel.
Investor Verification Checklist
- Verify the current closing bid price of UNCY stock to assess progress toward the $1.00 threshold.
- Monitor the Company's market capitalization to determine if it is approaching the $35 million MVLS requirement.
- Review subsequent filings for any announcements regarding reverse stock splits or other capital structure changes intended to address the deficiencies.
- Confirm the exact dates of the 10 consecutive business days required for compliance within the 180-day grace period.